Biomarin Pharmaceutical (BMRN) Research & Development (2017 - 2025)
Historic Research & Development for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to $409.5 million.
- Biomarin Pharmaceutical's Research & Development rose 12145.8% to $409.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $903.0 million, marking a year-over-year increase of 1578.37%. This contributed to the annual value of $747.2 million for FY2024, which is 5.5% up from last year.
- According to the latest figures from Q3 2025, Biomarin Pharmaceutical's Research & Development is $409.5 million, which was up 12145.8% from $161.3 million recorded in Q2 2025.
- Biomarin Pharmaceutical's Research & Development's 5-year high stood at $409.5 million during Q3 2025, with a 5-year trough of $148.7 million in Q1 2021.
- Moreover, its 5-year median value for Research & Development was $171.8 million (2023), whereas its average is $184.3 million.
- Data for Biomarin Pharmaceutical's Research & Development shows a peak YoY increase of 12145.8% (in 2025) and a maximum YoY decrease of 2256.53% (in 2025) over the last 5 years.
- Quarter analysis of 5 years shows Biomarin Pharmaceutical's Research & Development stood at $161.1 million in 2021, then grew by 7.24% to $172.8 million in 2022, then increased by 19.39% to $206.2 million in 2023, then decreased by 15.87% to $173.5 million in 2024, then soared by 136.0% to $409.5 million in 2025.
- Its Research & Development was $409.5 million in Q3 2025, compared to $161.3 million in Q2 2025 and $158.7 million in Q1 2025.